Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W Deininger

Showing results (11-20 of 160) with videos related to

Pageof 16
Sort By:
Leukemia Research|October 15, 2011
What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?Michael W Deininger, Paul Manley
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
Toward a cure for chronic myeloid leukemiaThomas O'Hare, Michael W Deininger
Haematologica|May 5, 2025
The birth of a paradigm: leukemia-initiating cells in acute myeloid leukemiaNataly Cruz-Rodriguez, Michael W Deininger
Leukemia & Lymphoma|December 18, 2020
Genetic complexity of chronic myelomonocytic leukemiaAmi B Patel, Michael W Deininger
Best Practice & Research. Clinical Haematology|December 5, 2009
Management of drug toxicities in chronic myeloid leukaemiaMichael J Mauro, Michael W Deininger
Seminars in Hematology|September 30, 2010
Resistance to imatinib: mutations and beyondPaul La Rosée, Michael W Deininger
Genome Biology|October 16, 2014
Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemiaAnna M Eiring, Michael W Deininger
Blood|December 27, 2024
Novel treatment strategies for chronic myeloid leukemiaNataly Cruz-Rodriguez, Michael W Deininger
Leukemia|October 1, 2020
Imatinib is not a potent anti-SARS-CoV-2 drugHelong Zhao, Michelle Mendenhall, Michael W Deininger
Blood Reviews|March 28, 2021
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directionsAfaf E G Osman, Michael W Deininger
Pageof 16

Showing results (11-20 of 160) with videos related to

Sort By:
Pageof 16
Leukemia Research|October 15, 2011
What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?Michael W Deininger, Paul Manley
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
Toward a cure for chronic myeloid leukemiaThomas O'Hare, Michael W Deininger
Haematologica|May 5, 2025
The birth of a paradigm: leukemia-initiating cells in acute myeloid leukemiaNataly Cruz-Rodriguez, Michael W Deininger
Leukemia & Lymphoma|December 18, 2020
Genetic complexity of chronic myelomonocytic leukemiaAmi B Patel, Michael W Deininger
Best Practice & Research. Clinical Haematology|December 5, 2009
Management of drug toxicities in chronic myeloid leukaemiaMichael J Mauro, Michael W Deininger
Seminars in Hematology|September 30, 2010
Resistance to imatinib: mutations and beyondPaul La Rosée, Michael W Deininger
Genome Biology|October 16, 2014
Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemiaAnna M Eiring, Michael W Deininger
Blood|December 27, 2024
Novel treatment strategies for chronic myeloid leukemiaNataly Cruz-Rodriguez, Michael W Deininger
Leukemia|October 1, 2020
Imatinib is not a potent anti-SARS-CoV-2 drugHelong Zhao, Michelle Mendenhall, Michael W Deininger
Blood Reviews|March 28, 2021
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directionsAfaf E G Osman, Michael W Deininger
Pageof 16